Publications by authors named "R B Kinsley"
Updates of SARS-CoV-2 vaccines are required to generate immunity in the population against constantly evolving SARS-CoV-2 variants of concerns (VOCs). Here we describe three novel in-silico designed spike-based antigens capable of inducing neutralising antibodies across a spectrum of SARS-CoV-2 VOCs. Three sets of antigens utilising pre-Delta (T2_32), and post-Gamma sequence data (T2_35 and T2_36) were designed.
View Article and Find Full Text PDFIntroduction: One of the unexpected outcomes of the COVID-19 pandemic was the relatively low levels of morbidity and mortality in Africa compared to the rest of the world. Nigeria, Africa's most populous nation, accounted for less than 0.01% of the global COVID-19 fatalities.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers developed a single antigen from the spike protein's receptor binding domain, which triggered strong immune responses in different animal models, including mice, rabbits, and guinea pigs against multiple SARS-related viruses.
- * The use of DNA and mRNA-based vaccine strategies demonstrated effective protection against the Delta variant of SARS-CoV-2 in genetically modified mice, emphasizing the potential for broad-spectrum coronavirus vaccines to prevent zoonotic spillovers.
The accelerated development of the first generation COVID-19 vaccines has saved millions of lives, and potentially more from the long-term sequelae of SARS-CoV-2 infection. The most successful vaccine candidates have used the full-length SARS-CoV-2 spike protein as an immunogen. As expected of RNA viruses, new variants have evolved and quickly replaced the original wild-type SARS-CoV-2, leading to escape from natural infection or vaccine induced immunity provided by the original SARS-CoV-2 spike sequence.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the immune responses in Lassa fever (LF) survivors and their contacts in Nigeria to understand natural protection and inform vaccine development.
- It finds that while both groups show similar T cell and antibody responses, neutralizing antibodies are predominantly present in LF survivors and provide cross-reactivity against various LASV strains.
- The research also highlights that immune responses diminish over time, suggesting potential vaccine targets in specific areas of the LASV Glycoprotein and Nucleoprotein for future clinical trials.